Cargando…
Robust immune responses after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals
The use of COVID-19 vaccines will play the major role in helping to end the pandemic that has killed millions worldwide. COVID-19 vaccines have resulted in robust humoral responses and protective efficacy in human trials, but efficacy trials excluded individuals with a prior diagnosis of COVID-19. A...
Autores principales: | Samanovic, Marie I., Cornelius, Amber R., Gray-Gaillard, Sophie L., Allen, Joseph Richard, Karmacharya, Trishala, Wilson, Jimmy P., Hyman, Sara Wesley, Tuen, Michael, Koralov, Sergei B., Mulligan, Mark J., Herati, Ramin Sedaghat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885942/ https://www.ncbi.nlm.nih.gov/pubmed/33594383 http://dx.doi.org/10.1101/2021.02.07.21251311 |
Ejemplares similares
-
Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals
por: Samanovic, Marie I., et al.
Publicado: (2021) -
Vaccine-Acquired SARS-CoV-2 Immunity versus Infection-Acquired Immunity: A Comparison of Three COVID-19 Vaccines
por: Samanovic, Marie I., et al.
Publicado: (2022) -
Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease
por: Haberman, Rebecca H, et al.
Publicado: (2021) -
Inflammation durably imprints memory CD4+ T cells
por: Gray-Gaillard, Sophie L., et al.
Publicado: (2023) -
High-titer neutralization of Mu and C.1.2 SARS-CoV-2 variants by vaccine-elicited antibodies of previously infected individuals
por: Tada, Takuya, et al.
Publicado: (2022)